Even if this study has been performed on a small cohort of patients, the indication is in line with the hypothesis and confirmed that a positive clinical outcome is linked to an activation of AMPK pathway, more precisely pACC, that might be considered a predictive marker for GBM response to regorafenib. Here, PRKAA2 is linked to glioblastoma.